drug
acoltremon
Marketedupdated 5mo agoby $ALC ALCON INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 28, 2030
~3.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Dec 16, 2042formulationUS 11850221
- Dec 16, 2042method-of-use (U-1900)US 12336971
- Sep 8, 2031method-of-use (U-1900)US 100289204.9y
- Sep 8, 2031formulationUS 90956094.9y
- Sep 8, 2031method-of-use (U-1900)US 94336794.9y
FDA exclusivities (1)
- May 28, 2030NCENew Chemical Entity (5y)3.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that